STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
Trial StartnegativeNegative
AI Analysis
Summary
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials. Cancer drug pricing has reached $480,000 as a routine market price.
Clinical Trial Data
Outcome Details
Multiple cell therapy trials paused
Importance:6/10
Sentiment:
-0.60
cell therapytrial pausedrug pricingcancer
Read the original article
Published by STAT News on September 1, 2026 1:21 PM